StockData
Kairos Pharma, LTD. logo

Kairos Pharma, LTD. (KAPA) income statement

KAPANYSEPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q3 năm tài chính 2026, quý kết thúc ngày Sep 30, 2026Last filing: 10-Q on Nov 13, 2026Score 6/30
$0.46+0.02 (+3.79%)

Close on Nov 19, 2026Market cap $1.70MP/E –Yield –

Kairos Pharma, LTD. income statement

Ratios

Latest available, balances at Sep 30, 2026

Profitability, FY

Gross margin
–
Operating margin
–
Net margin
–
Return on equity, FY2025
-98.0%

Financial strength

Current ratio
6.77
Debt to equity
–
Debt to assets
–
Cash to current liabilities
631.3%

Valuation

P/E ratio
–
Price to sales
–
Price to book
0.44
Dividend yield
–

See a number that looks wrong?